At the completion of this activity, the participant will be able to:
1. Describe the mechanism of action of KRAS G12C inhibitors and their current role in therapy for the treatment of NSCLC
2. Summarize efficacy and safety data from key KRAS G12C clinical trials
3. Recognize evidence-based strategies for the monitoring and management of adverse effects associated with KRAS G12C inhibitors

Session date: 
11/05/2025 - 1:00pm to 2:00pm EST
Location: 
AGH Lecture Hall (1st Floor ST); and Zoom Webinar
To Join the Zoom Webinar: https://highmarkhealth.zoom.us/j/98672570454?pwd=VU80YWJYNjgraGVsQ0xkU2xSNWozQT09
Meeting ID: 986 7257 0454; Passcode: 877628
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or register to take this course.